PharmaBoardroom

Stephan Mumenthaler – Director General, scienceindustries,…

scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how…

Philipp Maerz – Head of Northern Cluster & GM Norway,…

Philipp Maerz, the recently appointed head of Merck’s Nordic and Baltic operations and GM for Norway, outlines the challenges of taking on a new…

Axel Steiger – CEO, Bayer Switzerland

Axel Steiger, CEO and CFO for Bayer Switzerland, outlines the importance of the Swiss operations as one of the key global hubs for Bayer, his…

Peter Marks – Director, Center for Biologics Evaluation and…

Dr Peter Marks MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), highlights…

René P Buholzer – CEO, Interpharma, Switzerland (September…

Interpharma CEO Dr René P Buholzer outlines the holistic strategy that needs to be put in place to maintain Switzerland’s leading position in…

Asia-Pacific Pharma Partnerships News September 2020

The latest news from Asia-Pacific pharma, including Alovtech and DKSH’s biosimilar commercialisation partnership, Samsung Biologics and…

Ole Olesen – Executive Director, European Vaccine…

Ole Olesen, executive director of the European Vaccine Initiative (EVI), shares the highlights of his first nine months in the job grappling with a…

This Could Get Messy: Trump’s New ‘Most Favoured Nation’…

Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive…

Japan Market Entry: Opportunities & Challenges

Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park, gives an insider’s take on the opportunities and challenges for pharma…

Market Access in Asia: Hiring Access Executives Early is Crucial…

Robert Hall of Ardent Search, an executive search boutique specialised in the life sciences and healthcare sectors, highlights the five key points for…

Biosimilar Adoption in the US: Still Lagging Behind Europe

As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…

China Pharma Partnerships News Roundup September 2020

Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology…

Tagged with